HLS Therapeutics Announces Q1 Fiscal 2023 Financial Results

TORONTO, May 11, 2023 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system ("CNS") and cardiovascular markets, announces its financial results for the three-month period ended March 31, 2023. All amounts are in thousands of United States ("U.S.") dollars unless otherwise stated.

KEY HIGHLIGHTS

• Appointed Craig Millian as Chief Executive Officer of the Company.
• The Board of Directors cancelled the Company's dividend policy to focus on share buybacks through the Company's Normal Course Issuer Bid (NCIB) as the preferred method for returning capital to shareholders.
• Q1 2023 revenue was $14.8 million and Adjusted EBITDA was $5.1 million, compared to $14.6 million and $6.3 million, respectively, in Q1 2022

"Q1 results reflect the steady revenue and cash flow contribution from Clozaril and the royalty portfolio, as well as the continued growth of Vascepa," said Craig Millian, CEO of HLS. "On a constant currency basis, product sales in Canada were up 12% in Q1, led by Vascepa, which grew 43%."

"Having just started as CEO on May 1, I have already had an opportunity to meet with many of my HLS colleagues and have been impressed by their passion and commitment along with the potential of our product portfolio. My near-term goals are to accelerate the growth of Vascepa, maintain the durability of our CNS business and focus on resource optimization and efficiency."

Mr. Millian added: "After careful consideration, the board has decided to cancel the Company's dividend policy. HLS is a growth-oriented company, and this decision was made in the context of our capital allocation strategy and the desire to, among other things, return capital to shareholders via stock buybacks at a time when we believe that the share price does not reflect the underlying value of our business."

The final dividend will be paid on June 15, 2023, to shareholders of record on April 28, 2023, as was previously announced in the Company's March 16, 2023, press release.

VASCEPA 2023 OUTLOOK

The Company expects revenue growth for Vascepa to increase over the course of the year. The positive impact from strong prescription growth in Q1 2023 was partly offset by the payer mix being more weighted to public plans than was expected. As a result of the near-term impact of this payer mix, HLS is now guiding to the low end of its previously issued C$22-28 million revenue range for Vascepa in 2023.

Q1 2023 FINANCIAL & OPERATIONAL HIGHLIGHTS

• Clozaril net revenue in Canada in Q1 2023 was C$8.4 million, up 3% from Q1 2022, which was just ahead of the patient growth rate.
• Q1 2023 Vascepa net revenue was C$3.5 million, up 43% compared to C$2.5 million in Q1 2022. 
• Vascepa total prescriptions in Q1 2023 grew 94% year-over-year.
• Vascepa total prescriptions written by general practitioners grew 114% year-over-year and general practitioners now account for half of all new prescriptions written.
• More than 3,700 physicians have prescribed Vascepa, up 85% year-over-year.

Q1 FISCAL 2023 FINANCIAL REVIEW

The Company's Management's Discussion and Analysis and Consolidated Financial Statements for the three-month period ended March 31, 2023 are available at the Company's website and at its profile at SEDAR.

Revenue			Three months ended March 31,
			2023	2022
Product sales
Canada			8,811	8,403
United States			3,212	3,443
			12,023	11,846
Royalty revenue			2,734	2,710
			14,757	14,556

Product sales

Q1 2023 revenue increased 1% compared to Q1 2022. Q1 2023 revenue increased 5% in constant currency terms, compared to Q1 2022, as the decline in the Canadian dollar had an impact on the reported values, which are in U.S. dollars. Q1 2023 product sales in Canada increased 5% compared to Q1 2022. Q1 2023 product sales in Canada grew 12% in constant currency, compared to Q1 2022, led by increased sales of Vascepa, which grew 43% in Q1 2023 in constant currency compared to Q1 2022. The Vascepa net revenue growth rate trails the growth rate in prescriptions as net pricing adjusts to increased public sector volume.

In Canada, Clozaril continues to be the leading medication for treatment-resistant schizophrenia with a growing number of patients and a growing market share. Revenue declined 4% in Q1 2023, compared to Q1 2022, due to the weaker Canadian dollar during the period. On a constant currency basis, revenue in Q1 2023 increased 3% compared to Q1 2022.

In the U.S., Q1 2023 Clozaril net sales decreased 7% compared to Q1 2022. An increase in units sold and a price increase implemented mid-year 2022 resulted in higher gross revenues for Clozaril in the U.S. in Q1 2023, however, this was more than offset by larger one-time benefits realized in Q1 2022 related to expired product returns.

Royalty revenues

Representing a steady contribution to Adjusted EBITDA and cash flows, royalty revenues were $2.7 million in Q1 2023, which was a 1% increase from Q1 2022.  

Operating Expenses			Three months ended March 31,
			2023	2022
Cost of product sales			1,444	953
Selling and marketing			4,807	3,829
Medical, regulatory and patient support			1,076	1,276
General and administrative			2,351	2,182
			9,678	8,240

Q1 2023 operating expenses increased 17% compared to Q1 2022, which was driven by a 52% increase in cost of sales due to the growth in shipments and sales of Vascepa, and a 26% increase in selling and marketing costs for Vascepa.  Support costs and strong gross margins remain stable across the Company's key Clozaril franchises in Canada and the United States.

Adjusted EBITDA^1			Three months ended March 31,
			2023	2022
Net loss for the period			(5,792)	(3,616)
Stock-based compensation			(55)	815
Amortization and depreciation			8,319	8,387
Finance and related costs, net			2,434	320
Transaction and other costs			213	345
Income tax expense (recovery)			(40)	65
Adjusted EBITDA			5,079	6,316

Q1 2023 Adjusted EBITDA was $5.1 million compared to $6.3 million in Q1 2022. The decrease is due primarily to increased selling and marketing expenses and increased cost of product sales related to the growth in sales of Vascepa. Clozaril and royalty revenues continue to generate strong Adjusted EBITDA and cash flow for the business. 

¹ See "Cautionary Note Regarding Non-IFRS Measures" section of this press release.

Net Loss

Net loss for Q1 2023 was ($5.8 million), or ($0.18) per share, compared to a net loss of ($3.6 million), or ($0.11) per share, in Q1 2022. Net loss increased as revenue growth was offset by higher cost of product sales and selling and marketing expenses related to the expansion of Vascepa, as well as more typical finance and related costs in the current year. 

Cash from Operations and Financial Position

Cash generated from operations was $4.0 million in Q1 2023, compared to $5.8 million in Q1 2022. Cash and cash equivalents were $21.2 million at March 31, 2023 up from $20.7 million at December 31, 2022.

As at March 31, 2023, HLS has a strong financial position with $21.2 million of cash and cash equivalents, $26.5 million of undrawn revolving facility, and the Company may also request to be provided with incremental loans, up to a maximum amount of $70.0 million, to support acquisitions and other growth opportunities.

Q1 FISCAL 2023 CONFERENCE CALL

HLS will hold a conference call today at 8:30 am Eastern Time to discuss its Q1 2023 financial results. The call will be hosted by Mr. Craig Millian, CEO, and Mr. Tim Hendrickson, CFO. To view the slides that accompany management's discussion, please use the webcast link.

CONFERENCE ID:	63444923
DATE:	Thursday, May 11, 2023
TIME:	8:30 a.m. ET
WEBCAST LINK:	https://app.webinar.net/r3gVAnoY2xo
TRADITIONAL DIAL-IN NUMBER:	1-888-664-6392 or 416-764-8659
RAPIDCONNECT:	To instantly join the conference call by phone, please use the following URL to easily register and be connected into the conference call automatically: https://emportal.ink/3Gg7EBw
TAPED REPLAY:	1-888-390-0541 or 416-764-8677
REPLAY CODE:	444923#

The taped replay will be available for 14 days and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will also be available on the events page of the investors section of HLS Therapeutics' website at www.hlstherapeutics.com. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

ABOUT HLS THERAPEUTICS INC.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products targeting the central nervous system and cardiovascular therapeutic areas. HLS's management team is composed of seasoned pharmaceutical executives with a strong track record of success in these therapeutic areas and at managing products in each of these lifecycle stages. For more information visit: www.hlstherapeutics.com

¹CAUTIONARY NOTE REGARDING NON-IFRS MEASURES

This press release refers to certain non-IFRS measures. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of HLS's results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of HLS's financial information reported under IFRS. HLS uses non-IFRS measures to provide investors with supplemental measures of its operating performance and thus highlight trends in its core business that may not otherwise be apparent when relying solely on IFRS financial measures. HLS also believes that securities analysts, investors and other interested parties frequently use non-IFRS measures in the evaluation of issuers. HLS's management also uses non-IFRS measures in order to facilitate operating performance comparisons from period to period, prepare annual operating budgets and assess HLS's ability to meet its future debt service, capital expenditure and working capital requirements.

In particular, management uses Adjusted EBITDA as a measure of HLS's performance.  To reconcile net income (loss) for the period with Adjusted EBITDA, each of (i) "stock-based compensation", (ii) "amortization and depreciation", (iii) ("finance and related costs", (iv) "transaction and other costs", and (v) "income tax expense (recovery)" appearing in the Consolidated Statement of Net Income (Loss) are added to net income (loss) for the period to determine Adjusted EBITDA. Adjusted EBITDA does not have any standardized meaning prescribed by IFRS and is not necessarily comparable to similar measures presented by other companies.  Adjusted EBITDA should not be considered in isolation or as a substitute for net income (loss) prepared in accordance with IFRS as issued by the IASB.

FORWARD LOOKING INFORMATION

This release includes forward-looking statements regarding HLS and its business. Such statements are based on the current expectations and views of future events of HLS's management. In some cases the forward-looking statements can be identified by words or phrases such as "may", "will", "expect", "plan", "anticipate", "intend", "potential", "estimate", "believe" or the negative of these terms, or other similar expressions intended to identify forward-looking statements, including, among others, statements with respect to HLS's pursuit of additional product and pipeline opportunities in certain therapeutic markets, statements regarding growth opportunities, expectations regarding financial performance, and the NCIB and ASPP. The forward-looking events and circumstances discussed in this release may not occur and could differ materially as a result of known and unknown risk factors and uncertainties affecting HLS, including risks relating to the specialty pharmaceutical industry, risks related to the regulatory approval process, economic factors and many other factors beyond the control of HLS. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause HLS's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statement or information. Accordingly, readers should not place undue reliance on any forward-looking statements or information. A discussion of the material risks and assumptions associated with this release can be found in the Company's Annual Information Form dated March 15, 2023, and Management's Discussion and Analysis dated May 10, 2023, both of which have been filed on SEDAR and can be accessed at www.sedar.com. Accordingly, readers should not place undue reliance on any forward-looking statements or information. Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and HLS undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
Unaudited
[in thousands of U.S. dollars]
		As at	As at
		March 31, 2023	December 31, 2022
ASSETS
Current
Cash		21,214	20,723
Accounts receivable		10,096	10,999
Inventories		10,709	8,902
Income taxes recoverable		58	195
Other current assets		2,966	3,555
Total current assets		45,043	44,374
Property, plant and equipment		936	1,127
Intangible assets		186,984	195,018
Deferred tax asset		537	465
Other non-current assets		655	668
Total assets		234,155	241,652
LIABILITIES AND SHAREHOLDERS' EQUITY
Current
Accounts payable and accrued liabilities		14,433	12,785
Provisions		3,167	2,934
Debt and other liabilities		12,798	15,471
Total current liabilities		30,398	31,190
Debt and other liabilities		84,405	84,578
Deferred tax liability		461	566
Total liabilities		115,264	116,334
Shareholders' equity
Share capital		265,165	265,206
Contributed surplus		14,281	13,821
Accumulated other comprehensive loss		(5,167)	(5,260)
Deficit		(155,388)	(148,449)
Total shareholders' equity		118,891	125,318
Total liabilities and shareholders' equity		234,155	241,652

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF LOSS
Unaudited
[in thousands of U.S. dollars, except per share amounts]
				Three months ended March 31,
				2023	2022
Revenue				14,757	14,556
Expenses
Cost of product sales				1,444	953
Selling and marketing				4,807	3,829
Medical, regulatory and patient support				1,076	1,276
General and administrative				2,351	2,182
Stock-based compensation				(55)	815
Amortization and depreciation				8,319	8,387
Finance and related costs, net				2,434	320
Transaction and other costs				213	345
Loss before income taxes				(5,832)	(3,551)
Income tax expense (recovery)				(40)	65
Net loss for the period				(5,792)	(3,616)
Net loss per share:
Basic and diluted				$(0.18)	$(0.11)

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
Unaudited
[in thousands of U.S. dollars]
			Three months ended March 31,
			2023	2022
Net loss for the period			(5,792)	(3,616)
Item that may be reclassified subsequently to net loss
Unrealized foreign currency translation adjustment			93	2,438
Comprehensive loss for the period			(5,699)	(1,178)

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
Unaudited
[in thousands of U.S. dollars]
		Share capital	Contributed surplus	Accumulated other comprehensive income (loss)	Deficit	Total
Balance, December 31, 2022		265,206	13,821	(5,260)	(148,449)	125,318
Stock options exercised		178	(44)	—	—	134
Shares repurchased		(219)	—	—	35	(184)
Share purchase obligation		—	185	—	—	185
Stock option expense		—	319	—	—	319
Net loss for the period		—	—	—	(5,792)	(5,792)
Dividends declared		—	—	—	(1,182)	(1,182)
Unrealized foreign currency     translation adjustment		—	—	93	—	93
Balance, March 31, 2023		265,165	14,281	(5,167)	(155,388)	118,891
Balance, December 31, 2021		265,917	11,717	2,959	(119,857)	160,736
Stock options exercised		227	(62)	—	—	165
Shares repurchased		(15)	—	—	(6)	(21)
Stock option expense		—	609	—	—	609
Net loss for the period		—	—	—	(3,616)	(3,616)
Dividends declared		—	—	—	(1,282)	(1,282)
Unrealized foreign currency    translation adjustment		—	—	2,438	—	2,438
Balance, March 31, 2022		266,129	12,264	5,397	(124,761)	159,029

HLS THERAPEUTICS INC.
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
Unaudited
[in thousands of U.S. dollars]
		Three months ended March 31,
		2023	2022
OPERATING ACTIVITIES
Net loss for the period		(5,792)	(3,616)
Adjustments to reconcile net loss to cash provided by operating activities
Stock-based compensation		(55)	815
Amortization and depreciation		8,319	8,387
Accreted interest		191	207
Fair value adjustment on financial assets and liabilities		551	(1,474)
Deferred income taxes		(177)	409
Net change in non-cash working capital balances related to operations		983	1,030
Cash provided by operating activities		4,020	5,758
INVESTING ACTIVITIES
Additions to property, plant and equipment		—	(9)
Additions to intangible assets		—	(26)
Cash used in investing activities		—	(35)
FINANCING ACTIVITIES
Stock options exercised		134	165
Shares repurchased		(184)	(21)
Dividends paid		(1,182)	(1,282)
Repayment of credit agreement borrowing		(2,121)	(3,000)
Lease payments		(161)	(159)
Cash used in financing activities		(3,514)	(4,297)
Net increase in cash during the period		506	1,426
Foreign currency translation		(15)	59
Cash, beginning of period		20,723	21,179
Cash, end of period		21,214	22,664

SOURCE HLS Therapeutics Inc.

Dave Mason, Investor Relations, HLS Therapeutics Inc., [phone], [email protected]